Groundbreaking Results in the RE-LY® Trial – Novel Oral Direct Thrombin Inhibitor Dabigatran Etexilate Convincingly Beats Warfarin – Superior Stroke Reduction with Less Bleeding!

BusinessWireVideos

Best of Blip

About this episode

TV-UN

Professor Stuart Connolly, co-principal investigator of the RE-LY study, McMaster University, Hamilton, Canada, explains the results of the RE-LY trial in achieving superior stroke reduction for atrial fibrillation patients.

Discover the best in original web series.© 2012 Blip Networks, Inc. All Rights Reserved.